Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $9.71.

A number of brokerages recently issued reports on BCRX. Royal Bank Of Canada began coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. J P Morgan Chase & Co lifted their price objective on shares of BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Jefferies Group LLC raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the company from $5.00 to $7.00 in a research note on Wednesday, September 6th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/22/biocryst-pharmaceuticals-inc-bcrx-receives-consensus-recommendation-of-hold-from-analysts.html.

In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the sale, the director now owns 173,660 shares in the company, valued at $941,237.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its position in BioCryst Pharmaceuticals by 6.4% in the second quarter. The Manufacturers Life Insurance Company now owns 63,116 shares of the biotechnology company’s stock valued at $351,000 after buying an additional 3,774 shares in the last quarter. RA Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 47.9% in the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after buying an additional 1,672,447 shares in the last quarter. State Street Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 72.0% during the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after purchasing an additional 1,636,909 shares during the period. DAFNA Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 9.2% during the second quarter. DAFNA Capital Management LLC now owns 591,128 shares of the biotechnology company’s stock worth $3,287,000 after purchasing an additional 50,000 shares during the period. Finally, Tudor Investment Corp ET AL acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter worth $233,000. Hedge funds and other institutional investors own 70.21% of the company’s stock.

BioCryst Pharmaceuticals (NASDAQ BCRX) traded down 5.88% during midday trading on Friday, hitting $4.80. The stock had a trading volume of 1,237,109 shares. BioCryst Pharmaceuticals has a 1-year low of $3.75 and a 1-year high of $9.25. The company’s market cap is $471.99 million. The company’s 50 day moving average is $5.25 and its 200 day moving average is $5.54.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.79 million. During the same period in the prior year, the business posted ($0.22) earnings per share. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, equities analysts anticipate that BioCryst Pharmaceuticals will post ($0.75) earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.